A.L. Vataire - Concepedia

Author

A.L. Vataire

Creativ-Ceutical (France)ORCID

Also Known As

A Vataire, A. L. Vataire, A. Vataire, A.-L. Vataire, A.L. Vataire, Anne-Lise VATAIRE, Anne-Lise Vataire

Publications

659

Citations

H-Index

Concepts

All Affiliations

Creativ-Ceutical (France)Institut Gustave Roussy Université Claude Bernard Lyon 1 Inserm Medical University of Vienna

About

A.L. Vataire is an author at Creativ-Ceutical (France) specializing in medicine, oncology, and lung cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	191
2	Health Sciences	2	2	87
3	Nursing	1	1	15
4	Behavioral Health	1	1	15
5	Cell Biology	1	1	42

A.L. Vataire

Publications

393

Citations

H-Index

Page 1

	Year	Citations
Breast radiotherapy as part of loco-regional treatments in stage IV breast cancer patients with oligometastatic disease C. Bourgier, W. Khodari, A.L. Vataire, Radiotherapy and Oncology Surgical OncologyBreast OncologyRadiation TherapyBreast RadiotherapyLoco-regional Treatments	2010	72
ERCC1 and RRM1 in the International Adjuvant Lung Trial by Automated Quantitative in Situ Analysis Gerold Bepler, Ken A. Olaussen, A.L. Vataire, American Journal Of Pathology Situ AnalysisAdvanced Lung DiseaseMedicinePathologyBronchial Neoplasm	2011	62
Prediction and Diagnosis of Bone Metastases in Well-Differentiated Gastro-Entero-Pancreatic Endocrine Cancer: A Prospective Comparison of Whole Body Magnetic Resonance Imaging and Somatostatin Receptor Scintigraphy Sophie Leboulleux, Clarisse Dromain, A.L. Vataire, The Journal of Clinical Endocrinology & Metabolism	2008	45
Significance of <i>TP53</i> mutations as predictive markers of adjuvant cisplatin‐based chemotherapy in completely resected non‐small‐cell lung cancer Xiaoli Ma, Vanessa Rousseau, Haiji Sun, Molecular Oncology Adjuvant Cisplatin-based ChemotherapySurgical OncologyPredictive MarkersMedicineClinical Trials	2014	42
Economic Impact of Gene Expression Profiling in Patients with Early-Stage Breast Cancer in France Grégory Katz, Olivier Romano, Cyril Foa, PLoS ONE	2015	29
Cost-effectiveness comparison of cabozantinib with everolimus, axitinib, and nivolumab in the treatment of advanced renal cell carcinoma following the failure of prior therapy in England Jie Meng, J. Lister, A.L. Vataire, ClinicoEconomics and Outcomes Research	2018	24
Determinants of orphan drugs prices in France: a regression analysis D Korchagina, A. Millier, A.L. Vataire, Orphanet Journal of Rare Diseases	2017	20
Evaluation of the costs and resource use associated with adjuvant chemotherapy for breast cancer in France Enora Laas, A.L. Vataire, Samuel Aballéa, Journal of Medical Economics	2012	18
EU pharmaceutical expenditure forecast D. Urbinati, C. Rémuzat, A. Kornfeld, Journal of Market Access & Health Policy	2014	17
Does drinking water influence hospital-admitted sialolithiasis on an epidemiological level in Denmark? Stine Attrup Schrøder, Preben Homøe, Niels Wagner, BMJ Open	2015	16

Page 1